Completed PHASE2 INTERVENTIONAL NCT00411151

Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer

An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer

Sponsor: Johannes Gutenberg University Mainz

Conditions Barrett Esophagus Gastric Adenocarcinoma

Updated 6 times since 2017 Last updated: Jan 19, 2011 Started: Dec 31, 2006 Primary completion: Jul 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Barrett Esophagus and Gastric Adenocarcinoma, this trial is completed. The trial is conducted by Johannes Gutenberg University Mainz and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johannes Gutenberg University Mainz
Pfizer

Data source: Johannes Gutenberg University Mainz

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Cologne, Germany , Dresden, Germany , Essen, Germany , Frankfurt, Germany , Heidelberg, Germany , Homburg/Saar, Germany , Magdeburg, Germany , Mainz, Germany , München, Germany and 2 more locations